These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24659425)

  • 1. Promoter methylation of DAPK gene may contribute to the pathogenesis of nonsmall cell lung cancer: a meta-analysis.
    Li FF; Yang Y; Wang XL; Hong YY; Wang NF; Chen ZD
    Tumour Biol; 2014 Jun; 35(6):6011-20. PubMed ID: 24659425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study.
    Yang XY; Zhang J; Yu XL; Zheng GF; Zhao F; Jia XJ
    J Cancer Res Ther; 2018; 14(Supplement):S65-S71. PubMed ID: 29578152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance of DAPK gene promoter hypermethylation in non-small cell lung cancer: A meta-analysis.
    Chen Z; Fan Y; Liu X; Shang X; Qi K; Zhang S
    Int J Biol Markers; 2022 Mar; 37(1):47-57. PubMed ID: 34935548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAPK promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer.
    Zhang J; Yu XL; Zheng GF; Zhao F
    Cancer Biomark; 2015; 15(5):609-17. PubMed ID: 26406950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.
    Li Y; Zhu M; Zhang X; Cheng D; Ma X
    Drug Des Devel Ther; 2015; 9():1785-96. PubMed ID: 25848215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis.
    Dai L; Ma C; Zhang Z; Zeng S; Liu A; Tang S; Ren Q; Sun Y; Xu C
    PLoS One; 2016; 11(12):e0167228. PubMed ID: 27907054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant promoter methylation of the vimentin gene may contribute to colorectal carcinogenesis: a meta-analysis.
    Li YW; Kong FM; Zhou JP; Dong M
    Tumour Biol; 2014 Jul; 35(7):6783-90. PubMed ID: 24729088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.
    Li YS; Xie Q; Yang DY; Zheng Y
    Mol Biol Rep; 2014 Jun; 41(6):3925-33. PubMed ID: 24566681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.
    Dai D; Dong XH; Cheng ST; Zhu G; Guo XL
    Tumour Biol; 2014 Aug; 35(8):8209-16. PubMed ID: 24850174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between promoter methylation of DAPK gene and HNSCC: A meta-analysis.
    Cai F; Xiao X; Niu X; Zhong Y
    PLoS One; 2017; 12(3):e0173194. PubMed ID: 28249042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
    Si JG; Su YY; Han YH; Chen RH
    Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter methylation of the SFRP1 gene may contribute to colorectal carcinogenesis: a meta-analysis.
    Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
    Tumour Biol; 2014 Sep; 35(9):9201-10. PubMed ID: 24929326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effect of DAPK promoter methylation in gastric cancer: A systematic meta-analysis.
    Jia W; Yu T; Cao X; An Q; Yang H
    Medicine (Baltimore); 2016 Oct; 95(43):e5040. PubMed ID: 27787359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant promoter methylation of the CHD1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis.
    Gu X; Xue JQ; Zhu X; Ye MS; Zhang WH
    Tumour Biol; 2014 Sep; 35(9):9395-404. PubMed ID: 24952891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
    Li YX; Lu Y; Li CY; Yuan P; Lin SS
    DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant promoter methylation of RASSF1A gene may be correlated with colorectal carcinogenesis: a meta-analysis.
    Wang HL; Zhang Y; Liu P; Zhou PY
    Mol Biol Rep; 2014 Jun; 41(6):3991-9. PubMed ID: 24566684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients.
    Buckingham L; Penfield Faber L; Kim A; Liptay M; Barger C; Basu S; Fidler M; Walters K; Bonomi P; Coon J
    Int J Cancer; 2010 Apr; 126(7):1630-9. PubMed ID: 19795445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis.
    Wang H; Zhou LY; Guan ZB; Zeng WB; Zhou LL; Liu YN; Pan XY
    PLoS One; 2019; 14(1):e0210943. PubMed ID: 30682070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between MGMT promoter methylation and non-small cell lung cancer: a meta-analysis.
    Gu C; Lu J; Cui T; Lu C; Shi H; Xu W; Yuan X; Yang X; Huang Y; Lu M
    PLoS One; 2013; 8(9):e72633. PubMed ID: 24086261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.